Alejandro Gutierrez, M.D.


Boston Children's Hospital
Therapeutic Activation of the PP2A Tumor Suppressor in High-Risk T-cell Acute Lymphomblastic Leukemia

High‐risk T‐cell acute lymphoblastic leukemia (T‐ALL) is typically incurable with current therapy. We performed a zebrafish drug screen, which revealed that perphenazine (a clinical antipsychotic) has anti‐T‐ALL activity via reactivation of PP2A, an important tumor suppressor. Here, we will investigate the biology and therapeutic utility of PP2A reactivation in T‐ALL.